Spotlight on Oncology

Credits: 1.00 CME / CNE / CPE
Evolving Approaches for the Management of Waldenström’s Macroglobulinemia
Edward Libby, MD
Rush University Medical Center

Evolving Approaches for the Management of Waldenström’s Macroglobulinemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: November 12, 2019
Expires: November 11, 2020
1 hour to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  • Outline the criteria required to accurately diagnose patients with WM and identify those most likely to benefit from treatment
  • Describe the approved treatment paradigms for patients with WM
  • Discuss the mechanisms of action of novel investigational agents and review the clinical outcomes of these agents in patients with WM

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for Waldenström’s Macroglobulinemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Waldenström’s Macroglobulinemia , allowing for ease of assessment and incorporation into clinical practice.

Faculty

Edward Libby, MD
Fred Hutchinson Cancer Institute
Associate Professor, University of Washington
Seattle, WA


Edward Libby, MD, has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from BeiGene and Janssen Biotech, Inc., administered by Janssen Scientific Affairs.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: November 12, 2019
Expires: November 11, 2020
1 hour to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  • Outline the criteria required to accurately diagnose patients with WM and identify those most likely to benefit from treatment
  • Describe the approved treatment paradigms for patients with WM
  • Discuss the mechanisms of action of novel investigational agents and review the clinical outcomes of these agents in patients with WM

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for Waldenström’s Macroglobulinemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Waldenström’s Macroglobulinemia , allowing for ease of assessment and incorporation into clinical practice.

Faculty

Edward Libby, MD
Fred Hutchinson Cancer Institute
Associate Professor, University of Washington
Seattle, WA


Edward Libby, MD, has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from BeiGene and Janssen Biotech, Inc., administered by Janssen Scientific Affairs.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Oncology Presentations

1.00 CME / CNE / CPE
Rush University Medical Center
Incorporating Best Practices and Advancing Therapeutic Options in the Treatment of Multiple Myeloma

Incorporating Best Practices and Advancing Therapeutic Options in the Treatment of Multiple Myeloma

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: November 12, 2019
Expires: November 11, 2020
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Multiple Myeloma.

Learning Objectives

After completing this program, participants should be able to:
  • Outline recommendations for the diagnosis and risk stratification of patients with multiple myeloma and how this classification impacts treatment decisions throughout the disease continuum
  • Evaluate the changing therapeutic landscape for multiple myeloma including an understanding of finalized and ongoing clinical trials, emerging treatment options, and emerging real-world data on the use of novel targeted therapies
  • Implement the latest best-practice treatment strategies for optimizing care of patients with multiple myeloma, taking into consideration recent changes in clinical practice guidelines, evolving treatment paradigms, and expert recommendations

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Multiple Myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for Multiple Myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Multiple Myeloma, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Andrew Branagan, MD
Mass General Hospital
Boston, MA


Joshua Richter, MD
Mount Sinai Hospital
New York, NY


Robert Vescio, MD
Cedar Sinai Hospital
Los Angeles, CA


Conflict of Interest Policy/Disclosure Statement

Dr. Branagan is a consultant to Janssen, Pharmacyclines, and Surface Oncology.

Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen. Dr. Richter is also a Member, Speakers Bureau for Janssen and Celgene.

Dr. Vescio has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from Janssen Biotech, Inc. and Celgene.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: November 12, 2019
Expires: November 11, 2020
1 hour to complete

Accredited By

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Multiple Myeloma.

Learning Objectives

After completing this program, participants should be able to:
  • Outline recommendations for the diagnosis and risk stratification of patients with multiple myeloma and how this classification impacts treatment decisions throughout the disease continuum
  • Evaluate the changing therapeutic landscape for multiple myeloma including an understanding of finalized and ongoing clinical trials, emerging treatment options, and emerging real-world data on the use of novel targeted therapies
  • Implement the latest best-practice treatment strategies for optimizing care of patients with multiple myeloma, taking into consideration recent changes in clinical practice guidelines, evolving treatment paradigms, and expert recommendations

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Multiple Myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for Multiple Myeloma along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Multiple Myeloma, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Andrew Branagan, MD
Mass General Hospital
Boston, MA


Joshua Richter, MD
Mount Sinai Hospital
New York, NY


Robert Vescio, MD
Cedar Sinai Hospital
Los Angeles, CA


Conflict of Interest Policy/Disclosure Statement

Dr. Branagan is a consultant to Janssen, Pharmacyclines, and Surface Oncology.

Dr. Richter is a consultant to Karyopharm, BMS/Pfizer, Celgene, and Janssen. Dr. Richter is also a Member, Speakers Bureau for Janssen and Celgene.

Dr. Vescio has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from Janssen Biotech, Inc. and Celgene.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Evolving Approaches for the Management of Waldenström’s Macroglobulinemia

Evolving Approaches for the Management of Waldenström’s Macroglobulinemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: November 12, 2019
Expires: November 11, 2020
1 hour to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  • Outline the criteria required to accurately diagnose patients with WM and identify those most likely to benefit from treatment
  • Describe the approved treatment paradigms for patients with WM
  • Discuss the mechanisms of action of novel investigational agents and review the clinical outcomes of these agents in patients with WM

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for Waldenström’s Macroglobulinemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Waldenström’s Macroglobulinemia , allowing for ease of assessment and incorporation into clinical practice.

Faculty

Edward Libby, MD
Fred Hutchinson Cancer Institute
Associate Professor, University of Washington
Seattle, WA


Edward Libby, MD, has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from BeiGene and Janssen Biotech, Inc., administered by Janssen Scientific Affairs.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: November 12, 2019
Expires: November 11, 2020
1 hour to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.

Learning Objectives

After completing this program, participants should be able to:

  • Outline the criteria required to accurately diagnose patients with WM and identify those most likely to benefit from treatment
  • Describe the approved treatment paradigms for patients with WM
  • Discuss the mechanisms of action of novel investigational agents and review the clinical outcomes of these agents in patients with WM

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for Waldenström’s Macroglobulinemia along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Waldenström’s Macroglobulinemia , allowing for ease of assessment and incorporation into clinical practice.

Faculty

Edward Libby, MD
Fred Hutchinson Cancer Institute
Associate Professor, University of Washington
Seattle, WA


Edward Libby, MD, has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from BeiGene and Janssen Biotech, Inc., administered by Janssen Scientific Affairs.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.50 CME
Postgraduate Institute for Medicine
Expert Insights: Latest Approaches to Treating Lymphoma and Myeloma With CAR T-Cell Therapy

Expert Insights: Latest Approaches to Treating Lymphoma and Myeloma With CAR T-Cell Therapy

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: November 1, 2019
Expires: November 1, 2020
30 minutes to complete

Jointly Provided By

This activity is jointly provided by The Postgraduate Institute for Medicine and Bio Ascend.

Target Audience

The target audience for this symposium is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma and myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Explain the mechanism of action of CAR T-cell–based therapies and the rationale for their investigation and use in patients with lymphoma and multiple myeloma (MM)
  • Evaluate clinical data of current and emerging CAR T-cell therapies for patients with lymphoma
  • Assess clinical trial results from CAR T cells being investigated in patients with MM
  • Anticipate adverse events (AEs) that may occur with CAR T-cell therapy and develop strategies to mitigate these AEs

Activity Description

Expert Insights is an accredited, videotaped discussion featuring Dr. Julie Vose and Dr. Bianca Santomasso highlighting the most clinically relevant data on lymphoma and myeloma presented during a live symposium that was held at the 2019 Society of Hematologic Oncology Annual Meeting.

Statement of Educational Need

CAR T cells have emerged as a highly effective therapy in patients with hematologic malignancies. However, multiple CAR T technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with these agents need expert guidance to evaluate clinical data of CAR T therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.

Topics of Discussion

  • Overview of CAR T Cells and Current Data of Patients with Lymphoma
  • CAR T-Cell Therapy for Multiple Myeloma: The Future of Myeloma Care
  • Ongoing Efforts to Improve the Safety of CAR T-cell therapy: Cytokine Release Syndrome and Neurotoxicity

Faculty

Julie M. Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, NE

Grant Support: Amgen, Acerta Pharma, AstraZeneca, Birstol Myers Squibb, Celgene, Incyte Corp., Kite Pharma, Merck, Novartis, Seattle Genetics

Consultant: AbbVie, Epizyme, Novartis, Roche, Legend Pharmaceuticals, Kyopharm, Sandoz, Vaniam Group LLC, Janssen/Pharmacyclics, Kite Pharma, Acerta/AstraZeneca, Nordic Nanovector, Verastem, Beigene


Bianca Santomasso, MD, PhD
Neuro-Oncologist and Scientist
Memorial Sloan Kettering Cancer Center
New York, NY

Consultant: Kite/Gilead


Faculty and Planning Committee Disclosures

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
See faculty disclosures listed above.

Planners and Managers
The PIM planners and managers have nothing to disclose. The Bio Ascend planners and managers have nothing to disclose.

Accreditation Statement

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity.

During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit. Materials will be available online through November 1, 2020.

Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation and Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

cme@bioascend.com

For information about the continuing education of this activity, please contact Postgraduate Institute for Medicine (www.pimed.com) 1-800-423-3576 or email to inquiries@pimed.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: November 1, 2019
Expires: November 1, 2020
30 minutes to complete

Jointly Provided By

This activity is jointly provided by The Postgraduate Institute for Medicine and Bio Ascend.

Target Audience

The target audience for this symposium is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma and myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Explain the mechanism of action of CAR T-cell–based therapies and the rationale for their investigation and use in patients with lymphoma and multiple myeloma (MM)
  • Evaluate clinical data of current and emerging CAR T-cell therapies for patients with lymphoma
  • Assess clinical trial results from CAR T cells being investigated in patients with MM
  • Anticipate adverse events (AEs) that may occur with CAR T-cell therapy and develop strategies to mitigate these AEs

Activity Description

Expert Insights is an accredited, videotaped discussion featuring Dr. Julie Vose and Dr. Bianca Santomasso highlighting the most clinically relevant data on lymphoma and myeloma presented during a live symposium that was held at the 2019 Society of Hematologic Oncology Annual Meeting.

Statement of Educational Need

CAR T cells have emerged as a highly effective therapy in patients with hematologic malignancies. However, multiple CAR T technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with these agents need expert guidance to evaluate clinical data of CAR T therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.

Topics of Discussion

  • Overview of CAR T Cells and Current Data of Patients with Lymphoma
  • CAR T-Cell Therapy for Multiple Myeloma: The Future of Myeloma Care
  • Ongoing Efforts to Improve the Safety of CAR T-cell therapy: Cytokine Release Syndrome and Neurotoxicity

Faculty

Julie M. Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, NE

Grant Support: Amgen, Acerta Pharma, AstraZeneca, Birstol Myers Squibb, Celgene, Incyte Corp., Kite Pharma, Merck, Novartis, Seattle Genetics

Consultant: AbbVie, Epizyme, Novartis, Roche, Legend Pharmaceuticals, Kyopharm, Sandoz, Vaniam Group LLC, Janssen/Pharmacyclics, Kite Pharma, Acerta/AstraZeneca, Nordic Nanovector, Verastem, Beigene


Bianca Santomasso, MD, PhD
Neuro-Oncologist and Scientist
Memorial Sloan Kettering Cancer Center
New York, NY

Consultant: Kite/Gilead


Faculty and Planning Committee Disclosures

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
See faculty disclosures listed above.

Planners and Managers
The PIM planners and managers have nothing to disclose. The Bio Ascend planners and managers have nothing to disclose.

Accreditation Statement

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity.

During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit. Materials will be available online through November 1, 2020.

Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation and Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

cme@bioascend.com

For information about the continuing education of this activity, please contact Postgraduate Institute for Medicine (www.pimed.com) 1-800-423-3576 or email to inquiries@pimed.com

1.00 CME / CNE / CPE
Rush University Medical Center
Advancing Treatment Options in the Management of Head and Neck Cancers

Advancing Treatment Options in the Management of Head and Neck Cancers

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 8, 2019
Expires: October 7, 2020
1 hour to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Head and Neck Cancers.

Learning Objectives

After completing this program, participants should be able to:

  • Summarize current best practice approaches for the management of head & neck cancer patients in the VHA, DoD and MHS settings
  • Discuss present and future clinical trials in head & neck cancer patients
  • Assess the role of immunotherapy in head & neck cancer patients

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Head and Neck Cancers. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for Head and Neck Cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Head and Neck Cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Mark Klein, MD
Assistant Professor of Medicine
University of Minnesota
Minneapolis, MN


Conflict of Interest Policy/Disclosure Statement

Mark Klein, MD has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Merck, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 8, 2019
Expires: October 7, 2020
1 hour to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Head and Neck Cancers.

Learning Objectives

After completing this program, participants should be able to:

  • Summarize current best practice approaches for the management of head & neck cancer patients in the VHA, DoD and MHS settings
  • Discuss present and future clinical trials in head & neck cancer patients
  • Assess the role of immunotherapy in head & neck cancer patients

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of Head and Neck Cancers. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for Head and Neck Cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with Head and Neck Cancer, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Mark Klein, MD
Assistant Professor of Medicine
University of Minnesota
Minneapolis, MN


Conflict of Interest Policy/Disclosure Statement

Mark Klein, MD has no conflict of interest with any commercial interest(s) whose products or services may be mentioned in this activity.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from Merck, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.75 CME
Postgraduate Institute for Medicine
Podium to Practice: Updates from Chicago, Amsterdam, and Lugano Regarding Clinical Updates of Ongoing Trials in Chronic Lymphocytic Leukemia and Follicular Lymphoma

Podium to Practice: Updates from Chicago, Amsterdam, and Lugano Regarding Clinical Updates of Ongoing Trials in Chronic Lymphocytic Leukemia and Follicular Lymphoma

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: September 24, 2019
Expires: September 24, 2020
45 minutes to complete

Jointly Provided By

This activity is jointly provided by The Postgraduate Institute for Medicine and Bio Ascend.

Target Audience

The target audience for this activity is hematologists/oncologists, bone marrow transplant clinicians, and other healthcare professionals (oncology nurses and pharmacists, physician assistants, etc.) interested and/or involved in the treatment of patients with CLL/FL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review clinical trial data of current and emerging therapies that are being investigated in patients with CLL
  • Evaluate the safety and efficacy data from clinical studies that are examining various treatment options and regimens in patients with FL
  • Discuss common adverse events that are associated with these therapies, and develop approaches to mitigate such adverse events
  • As new agents and regimens become available, develop strategies to safely and effectively integrate these treatment approaches in order to maximize patient outcomes

Activity Description

Podium to Practice is a CME-certified activity featuring two renowned experts who are actively engaged in the management and treatment of patients with chronic lymphocytic leukemia and follicular lymphoma.

Statement of Educational Need

The management of FL and CLL is currently undergoing a dynamic, rapid, and very positive development. It is anticipated that the combination of targeted and non-chemotherapeutic drugs such as obinutuzumab, ibrutinib, idelalisib, and venetoclax will lead to deep, molecular, and long-lasting remissions. Clinicians will need to stay abreast of this changing landscape in order to offer their patients improved benefits, and potentially enroll eligible patients into clinical trials to examine novel therapies.

Topics of Discussion

  • Clinical data of trials being performed in newly diagnosed patients with CLL or FL
  • Trial results of agents being investigated in patients with relapsed/refractory CLL or FL
  • Common AEs observed with investigational agents/regimens
  • Strategies for integrating novel agents/regimens into practice that may be approved in the near future

Faculty

Jennifer Brown, MD, PhD
Director, Chronic Lymphocytic Leukemia Center
Institute Physician
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Consulting Fees: Acerta Pharma, Celgene Corporation, Gilead Sciences, Inc., Pharmacyclics LLC, Sandoz


Jacqueline Barrientos, MD
Associate Professor
Department of Medicine
Zucker School of Medicine at Hofstra/Northwell
CLL Research and Treatment Program
Feinstein Institutes for Medical Research
Northwell Health
New Hyde Park, New York

Consulting Fees: AbbVie Inc., Acerta Pharma, AstraZeneca, BeiGene, Catapult Therapeutics, Dynamo Therapeutics, Inc., Juno/Celgene, Kite Pharma, Octapharma AG, Novartis, Pharmacyclics LLC, Sunesis Pharmaceuticals, Inc., TG Therapeutics, Inc., Verastem, Inc. 

Honorarium: Janssen, Teva Contracted Research: Gilead Sciences, Inc., Loxo Oncology, Sun, Verastem, Inc.

Other (Data Safety Monitoring Committee): MorphoSys AG, Invectys


Disclosure of Conflicts of Interests

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Accreditation Statement

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There is no fee for this educational activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Materials will be available online through September 24, 2020.

Statement of Commercial Support

This activity is supported by independent educational grants from Gilead Sciences, Inc. and Verastem, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

PIM and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of PIM and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: September 24, 2019
Expires: September 24, 2020
45 minutes to complete

Jointly Provided By

This activity is jointly provided by The Postgraduate Institute for Medicine and Bio Ascend.

Target Audience

The target audience for this activity is hematologists/oncologists, bone marrow transplant clinicians, and other healthcare professionals (oncology nurses and pharmacists, physician assistants, etc.) interested and/or involved in the treatment of patients with CLL/FL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review clinical trial data of current and emerging therapies that are being investigated in patients with CLL
  • Evaluate the safety and efficacy data from clinical studies that are examining various treatment options and regimens in patients with FL
  • Discuss common adverse events that are associated with these therapies, and develop approaches to mitigate such adverse events
  • As new agents and regimens become available, develop strategies to safely and effectively integrate these treatment approaches in order to maximize patient outcomes

Activity Description

Podium to Practice is a CME-certified activity featuring two renowned experts who are actively engaged in the management and treatment of patients with chronic lymphocytic leukemia and follicular lymphoma.

Statement of Educational Need

The management of FL and CLL is currently undergoing a dynamic, rapid, and very positive development. It is anticipated that the combination of targeted and non-chemotherapeutic drugs such as obinutuzumab, ibrutinib, idelalisib, and venetoclax will lead to deep, molecular, and long-lasting remissions. Clinicians will need to stay abreast of this changing landscape in order to offer their patients improved benefits, and potentially enroll eligible patients into clinical trials to examine novel therapies.

Topics of Discussion

  • Clinical data of trials being performed in newly diagnosed patients with CLL or FL
  • Trial results of agents being investigated in patients with relapsed/refractory CLL or FL
  • Common AEs observed with investigational agents/regimens
  • Strategies for integrating novel agents/regimens into practice that may be approved in the near future

Faculty

Jennifer Brown, MD, PhD
Director, Chronic Lymphocytic Leukemia Center
Institute Physician
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Consulting Fees: Acerta Pharma, Celgene Corporation, Gilead Sciences, Inc., Pharmacyclics LLC, Sandoz


Jacqueline Barrientos, MD
Associate Professor
Department of Medicine
Zucker School of Medicine at Hofstra/Northwell
CLL Research and Treatment Program
Feinstein Institutes for Medical Research
Northwell Health
New Hyde Park, New York

Consulting Fees: AbbVie Inc., Acerta Pharma, AstraZeneca, BeiGene, Catapult Therapeutics, Dynamo Therapeutics, Inc., Juno/Celgene, Kite Pharma, Octapharma AG, Novartis, Pharmacyclics LLC, Sunesis Pharmaceuticals, Inc., TG Therapeutics, Inc., Verastem, Inc. 

Honorarium: Janssen, Teva Contracted Research: Gilead Sciences, Inc., Loxo Oncology, Sun, Verastem, Inc.

Other (Data Safety Monitoring Committee): MorphoSys AG, Invectys


Disclosure of Conflicts of Interests

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Accreditation Statement

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There is no fee for this educational activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Materials will be available online through September 24, 2020.

Statement of Commercial Support

This activity is supported by independent educational grants from Gilead Sciences, Inc. and Verastem, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

PIM and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of PIM and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

0.50 CME
University of Nebraska Medical Center
Expert Insights - New Treatments and New Targets for the Treatment of Prostate Cancer: Expanding Options Along the Disease Continuum

Expert Insights - New Treatments and New Targets for the Treatment of Prostate Cancer: Expanding Options Along the Disease Continuum

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit
Released: September 16, 2019
Expires: September 16, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

This target audience for this activity is community and academic medical oncologists, urologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with prostate cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss treatment strategies for nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) that delay progression to metastatic CRPC
  • Evaluate currently available treatment options for patients with CRPC
  • Identify prostate cancer patients who may benefit from biomarker-directed therapy
  • Assess clinical trial data of emerging therapeutic strategies that may impact the future landscape of mCRPC

Activity Description

Podium to Practice is a CME-certified activity featuring two renowned experts who are actively engaged in clinical trials and the management of patients with nonmetastatic castration-resistant prostate cancer.

Faculty

Neal Shore, MD, FACS - Moderator
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Research, Consultant: AbbVie Inc., Amgen Inc., AstraZeneca, Bayer, Bristol-Myers Squibb Company, Color Genomics, Inc., Dendreon Pharmaceuticals, LLC., Ferring Pharmaceuticals, Genentech-Roche, Genomic Health, Invitae Corporation, Janssen, Merck Sharp & Dohme Corp., Myriad Genetics, Inc., Nymox Pharmaceutical Corporation, Pfizer Inc., Sanofi-Genzyme, Tolmar Pharmaceuticals, Inc.


Charles Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Advisor: Bayer HealthCare Corporation, Clovis Oncology, Janssen, Sanofi-Genzyme


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA approved. Participants should note that the use of products outside currently FDA approved labeling should be considered experimental and are advised to consult current prescribing information for FDA approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

All conference faculty and planning committee members have no conflicts to disclose with the exceptions listed below.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Materials will be available online through September 16, 2020.

Statement of Commercial Support

This activity is supported by independent educational grants from Astellas and Pfizer, Inc. and Bayer HealthCare Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions about the Activity

cme@bioascend.com

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit
Released: September 16, 2019
Expires: September 16, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

This target audience for this activity is community and academic medical oncologists, urologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with prostate cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss treatment strategies for nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) that delay progression to metastatic CRPC
  • Evaluate currently available treatment options for patients with CRPC
  • Identify prostate cancer patients who may benefit from biomarker-directed therapy
  • Assess clinical trial data of emerging therapeutic strategies that may impact the future landscape of mCRPC

Activity Description

Podium to Practice is a CME-certified activity featuring two renowned experts who are actively engaged in clinical trials and the management of patients with nonmetastatic castration-resistant prostate cancer.

Faculty

Neal Shore, MD, FACS - Moderator
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Research, Consultant: AbbVie Inc., Amgen Inc., AstraZeneca, Bayer, Bristol-Myers Squibb Company, Color Genomics, Inc., Dendreon Pharmaceuticals, LLC., Ferring Pharmaceuticals, Genentech-Roche, Genomic Health, Invitae Corporation, Janssen, Merck Sharp & Dohme Corp., Myriad Genetics, Inc., Nymox Pharmaceutical Corporation, Pfizer Inc., Sanofi-Genzyme, Tolmar Pharmaceuticals, Inc.


Charles Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Advisor: Bayer HealthCare Corporation, Clovis Oncology, Janssen, Sanofi-Genzyme


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA approved. Participants should note that the use of products outside currently FDA approved labeling should be considered experimental and are advised to consult current prescribing information for FDA approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

All conference faculty and planning committee members have no conflicts to disclose with the exceptions listed below.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; and 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Materials will be available online through September 16, 2020.

Statement of Commercial Support

This activity is supported by independent educational grants from Astellas and Pfizer, Inc. and Bayer HealthCare Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions about the Activity

cme@bioascend.com

0.50 CNE
University of Nebraska Medical Center
Expert Insights: Patient and Nurse Perspectives on the Use of PARP Inhibitors for Ovarian Cancer: Strategies for Maximizing Patient Outcomes

Expert Insights: Patient and Nurse Perspectives on the Use of PARP Inhibitors for Ovarian Cancer: Strategies for Maximizing Patient Outcomes

Start

Activity Details

Free CNE
0.5 Contact Hours
Released: September 11, 2019
Expires: September 11, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, College of Nursing Continuing Nursing Education

Learning Objectives

After completing this activity, participants should be better able to:

  • Identify patients with ovarian cancer who are most appropriate to receive treatment with PARP inhibitors
  • Evaluate recent clinical updates and novel indications of PARP inhibitors for the treatment of patients with ovarian cancer
  • Discuss approaches for PARP inhibitors that incorporate patient perspectives regarding maintenance therapy
  • Assess nursing interventions and treatment management strategies to prevent and mitigate therapeutic-related adverse events, including the utilization of dose modification guidelines

Activity Description

Expert Insights captures a stimulating and informative conversation about patient selection for PARP inhibitor therapy, a review of clinical data, and strategies for managing common adverse events that occur with PARP inhibitor therapy for ovarian cancer.

Statement of Educational Need

Because of the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, nurses are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, nurses treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications into practice when they become available, in consideration of patient needs and preferences.

Faculty

Paula Anastasia, RN, MN, AOCN - Moderator
Gynecologic Oncology, Clinical Nurse Specialist
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California


Kimberly Halla, MSN, FNP-C
Gynecologic Oncology, Nurse Practitioner
Arizona Oncology
Phoenix, Arizona


Conflict of Interest Policy/Disclosure Statement

All planners and faculty participating in continuing education activities provided by the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education (UNMC CON CNE) are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
 
The following speakers and planning committee members listed below have stated they have no financial relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity.

  • Paula Anastasia, RN, MN, AOCN
  • Dru S. Dace, PhD
  • Kimberly Halla, MSN, FNP-C
  • Heidi Keeler, PhD, RN
  • Renee Paulin, MSN, RN, CWOCN
  • Kraig Steubing, BS

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

The opinions expressed in the educational activity do not necessarily represent the views of UNMC CON CNE and Bio Ascend, LLC.

Accreditation Statement and Joint Providership

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

This activity is provided for 0.5 contact hours under ANCC criteria.

UNMC CON CNE has been awarded Accreditation with Distinction, the highest recognition awarded by the ANCC’s Accreditation Program. This distinction is valid through 2020.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ANCC’s Commission on Accreditation through the joint providership of UNMC CON CNE (provider) and Bio Ascend, LLC.

Accredited status as a provider of continuing nursing education refers only to UNMC CON CNE continuing education activities, and does not imply UNMC or ANCC’s Commission on Accreditation endorsement of any commercial supporters.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 30 minutes. In order to receive contact hours, you must complete the following prior to the activity expiration date of September 11, 2020: 1) Read the continuing nursing education disclosures and disclaimers related to this activity; 2) Complete the pre-test; 3) Watch the presentation; 4) Successfully complete the post-test with a score of 66% (2/3) or better; 5) Complete the contact information and evaluation forms. Your certificate of completion will be available to download or print upon successful completion of the post-test and submission of your contact information and evaluation.

Statement of Commercial Support

The UNMC College of Nursing CNE Program and Bio Ascend thank the following companies for their generous support of this program in the form of educational grants: AstraZeneca and Tesaro, Inc.

Activity Details

Free CNE
0.5 Contact Hours
Released: September 11, 2019
Expires: September 11, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, College of Nursing Continuing Nursing Education

Learning Objectives

After completing this activity, participants should be better able to:

  • Identify patients with ovarian cancer who are most appropriate to receive treatment with PARP inhibitors
  • Evaluate recent clinical updates and novel indications of PARP inhibitors for the treatment of patients with ovarian cancer
  • Discuss approaches for PARP inhibitors that incorporate patient perspectives regarding maintenance therapy
  • Assess nursing interventions and treatment management strategies to prevent and mitigate therapeutic-related adverse events, including the utilization of dose modification guidelines

Activity Description

Expert Insights captures a stimulating and informative conversation about patient selection for PARP inhibitor therapy, a review of clinical data, and strategies for managing common adverse events that occur with PARP inhibitor therapy for ovarian cancer.

Statement of Educational Need

Because of the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, nurses are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, nurses treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications into practice when they become available, in consideration of patient needs and preferences.

Faculty

Paula Anastasia, RN, MN, AOCN - Moderator
Gynecologic Oncology, Clinical Nurse Specialist
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California


Kimberly Halla, MSN, FNP-C
Gynecologic Oncology, Nurse Practitioner
Arizona Oncology
Phoenix, Arizona


Conflict of Interest Policy/Disclosure Statement

All planners and faculty participating in continuing education activities provided by the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education (UNMC CON CNE) are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
 
The following speakers and planning committee members listed below have stated they have no financial relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity.

  • Paula Anastasia, RN, MN, AOCN
  • Dru S. Dace, PhD
  • Kimberly Halla, MSN, FNP-C
  • Heidi Keeler, PhD, RN
  • Renee Paulin, MSN, RN, CWOCN
  • Kraig Steubing, BS

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

The opinions expressed in the educational activity do not necessarily represent the views of UNMC CON CNE and Bio Ascend, LLC.

Accreditation Statement and Joint Providership

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

This activity is provided for 0.5 contact hours under ANCC criteria.

UNMC CON CNE has been awarded Accreditation with Distinction, the highest recognition awarded by the ANCC’s Accreditation Program. This distinction is valid through 2020.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ANCC’s Commission on Accreditation through the joint providership of UNMC CON CNE (provider) and Bio Ascend, LLC.

Accredited status as a provider of continuing nursing education refers only to UNMC CON CNE continuing education activities, and does not imply UNMC or ANCC’s Commission on Accreditation endorsement of any commercial supporters.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 30 minutes. In order to receive contact hours, you must complete the following prior to the activity expiration date of September 11, 2020: 1) Read the continuing nursing education disclosures and disclaimers related to this activity; 2) Complete the pre-test; 3) Watch the presentation; 4) Successfully complete the post-test with a score of 66% (2/3) or better; 5) Complete the contact information and evaluation forms. Your certificate of completion will be available to download or print upon successful completion of the post-test and submission of your contact information and evaluation.

Statement of Commercial Support

The UNMC College of Nursing CNE Program and Bio Ascend thank the following companies for their generous support of this program in the form of educational grants: AstraZeneca and Tesaro, Inc.

0.50 CME
University of Nebraska Medical Center
Podium to Practice: Updates from Chicago Regarding Recent Advances in CAR T-cell Therapy for the Treatment of Hematologic Malignancies

Podium to Practice: Updates from Chicago Regarding Recent Advances in CAR T-cell Therapy for the Treatment of Hematologic Malignancies

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: July 17, 2019
Expires: July 17, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who are interested in the use of CAR T-cell therapy for the treatment of patients with hematologic malignancies.

Learning Objectives

After completing this activity, participants should be better able to:

  • Review clinical trial data of current and emerging CAR T-cell therapies that are being investigated in patients with hematologic malignancies, including lymphoma, leukemia, and multiple myeloma
  • Discuss the potential for using CAR T-cell-based therapies in patients with other malignancies
  • Discuss common adverse events that are associated with CAR T-cell therapy, and develop strategies to mitigate such adverse events

Activity Description

Podium to Practice is a discussion among two renowned experts actively engaged in clinical trials and the management of patients with CAR T cells. This exchange features expert summary and interpretation of data presented during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, and provides guidance on the optimal use of CAR T cells for patients with hematologic malignancies.

Statement of Educational Need

CAR T cells have emerged as a highly effective therapy in patients with hematologic malignancies and show promise in patients with solid tumors. However, multiple CAR T technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with these agents need expert guidance to evaluate clinical data of CAR T therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.

Faculty

Matthew Lunning, DO - Moderator
Associate Professor
Internal Medicine
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Consulting Fees: AbbVie, Inc., Bayer, Celgene Corporation, DAVA, Gilead Sciences, Inc., Janssen, Juno Therapeutics, Kite Pharma, Novartis, OncLive, Portola, Seattle Genetics, Spectrum Pharmaceuticals, TG Therapeutics, Vaniam Group, Verastem
Grants/Research Support: Celgene Corporation, Curis, Janssen Scientific Affairs, LLC, Juno Therapeutics, MiRagen, TG Therapeutics


Reem Karmali, MD, MS
Assistant Professor
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

Advisory Board: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma
Grants/Research Support: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma, Takeda Pharmaceutical Company Ltd
Speakers Bureau: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma


Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

This program may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
cme@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: July 17, 2019
Expires: July 17, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who are interested in the use of CAR T-cell therapy for the treatment of patients with hematologic malignancies.

Learning Objectives

After completing this activity, participants should be better able to:

  • Review clinical trial data of current and emerging CAR T-cell therapies that are being investigated in patients with hematologic malignancies, including lymphoma, leukemia, and multiple myeloma
  • Discuss the potential for using CAR T-cell-based therapies in patients with other malignancies
  • Discuss common adverse events that are associated with CAR T-cell therapy, and develop strategies to mitigate such adverse events

Activity Description

Podium to Practice is a discussion among two renowned experts actively engaged in clinical trials and the management of patients with CAR T cells. This exchange features expert summary and interpretation of data presented during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, and provides guidance on the optimal use of CAR T cells for patients with hematologic malignancies.

Statement of Educational Need

CAR T cells have emerged as a highly effective therapy in patients with hematologic malignancies and show promise in patients with solid tumors. However, multiple CAR T technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with these agents need expert guidance to evaluate clinical data of CAR T therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.

Faculty

Matthew Lunning, DO - Moderator
Associate Professor
Internal Medicine
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Consulting Fees: AbbVie, Inc., Bayer, Celgene Corporation, DAVA, Gilead Sciences, Inc., Janssen, Juno Therapeutics, Kite Pharma, Novartis, OncLive, Portola, Seattle Genetics, Spectrum Pharmaceuticals, TG Therapeutics, Vaniam Group, Verastem
Grants/Research Support: Celgene Corporation, Curis, Janssen Scientific Affairs, LLC, Juno Therapeutics, MiRagen, TG Therapeutics


Reem Karmali, MD, MS
Assistant Professor
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

Advisory Board: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma
Grants/Research Support: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma, Takeda Pharmaceutical Company Ltd
Speakers Bureau: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma


Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

This program may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
cme@bioascend.com

1.00 CME / CNE / CPE
Rush University Medical Center
Expert Perspectives in the Management of Chronic Lymphocytic Leukemia: Integrating Current and Emerging Agents/Regimens to Develop Evidence Based Clinical Management Strategies

Expert Perspectives in the Management of Chronic Lymphocytic Leukemia: Integrating Current and Emerging Agents/Regimens to Develop Evidence Based Clinical Management Strategies

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 2, 2019
Expires: July 1, 2020
1 hour to complete

Accredited by

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Chronic Lymphocytic Leukemia.

Learning Objectives

After completing this program, participants should be able to:

1: Apply the latest data to risk stratify and optimize treatment plans for patients with CLL based on prognostic and predictive markers

2: Differentiate between first-line and relapsed/refractory treatment approaches for the treatment of CLL using the latest evidence-based guidelines

3: Explain the emerging clinical data and ongoing trials on novel agents and therapeutic strategies that have the potential to improve patient outcomes for patients with CLL

4: Summarize evidence-based management strategies that can be used to identify and treat acute and long-term complications associated with CLL treatment including: barriers to treatment, adherence, comorbidities, advanced age, etc.

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for CLL along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with CLL, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Jonathon B. Cohen, MD, MS (Course Director)
Department of Hematology and Medical Oncology
Emory University
Winship Cancer Institute
Atlanta, GA


Conflict of Interest Policy/Disclosure Statement

Jonathon B. Cohen, MD, MS, has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity.

Advisor: Janssen, Genentech
Research Funding: Genentech

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from AbbVie, Inc, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and TG Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 2, 2019
Expires: July 1, 2020
1 hour to complete

Accredited by

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Chronic Lymphocytic Leukemia.

Learning Objectives

After completing this program, participants should be able to:

1: Apply the latest data to risk stratify and optimize treatment plans for patients with CLL based on prognostic and predictive markers

2: Differentiate between first-line and relapsed/refractory treatment approaches for the treatment of CLL using the latest evidence-based guidelines

3: Explain the emerging clinical data and ongoing trials on novel agents and therapeutic strategies that have the potential to improve patient outcomes for patients with CLL

4: Summarize evidence-based management strategies that can be used to identify and treat acute and long-term complications associated with CLL treatment including: barriers to treatment, adherence, comorbidities, advanced age, etc.

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for CLL along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with CLL, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Jonathon B. Cohen, MD, MS (Course Director)
Department of Hematology and Medical Oncology
Emory University
Winship Cancer Institute
Atlanta, GA


Conflict of Interest Policy/Disclosure Statement

Jonathon B. Cohen, MD, MS, has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity.

Advisor: Janssen, Genentech
Research Funding: Genentech

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from AbbVie, Inc, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and TG Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

0.25 CME
AXIS
Expert Answers to Common Questions for Optimizing the Use of CDK4 and CDK6 Inhibitors for Metastatic Breast Cancer

Expert Answers to Common Questions for Optimizing the Use of CDK4 and CDK6 Inhibitors for Metastatic Breast Cancer

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit
Released: March 26, 2019
Expires: March 25, 2020
15 minutes to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who treat or manage advanced or metastatic breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Describe the mechanism of action of cyclin-dependent kinase 4/6 inhibitors, including differences among available and emerging agents
  • Compare and contrast the dosing and efficacy of cyclin-dependent kinase 4/6 inhibitors for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer
  • Select the appropriate cyclin-dependent kinase 4/6 inhibitor for patients according to their efficacy, safety, and patient characteristics
  • Identify common toxicities of cyclin-dependent kinase 4/6 inhibitors for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer, including gastrointestinal toxicity and neutropenia

Activity Description

Recently, there have been significant advances in the development of agents that target critical pathways involved in resistance to endocrine therapy in HR-positive/HER2-negative breast cancer, such as cyclin-dependent kinase (CDK) 4/6 inhibitors,  palbociclib, abemaciclib, and ribociclib.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on CDK4/6 inhibitors for the treatment of advanced HR-positive/HER2-negative breast cancer.

Statement of Educational Need

The goal of this activity is to provide expert perspective on frequently asked questions pertaining to the use of CDK4 and CDK6 inhibitors for the treatment of HR-positive/HER2-negative advanced or metastatic breast cancer so clinicians gain an enhanced understanding of this disease to make the best possible treatment choices with their patients.

Faculty

Adam M. Brufsky, MD, PhD, FACP
Professor of Medicine / Associate Chief, Hematology-Oncology / Associate Director, Translational Research
University of Pittsburgh School of Medicine
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Adam M. Brufsky, MD, PhD, FACP
  • Adam M. Brufsky, MD, PhD, FACP, reported a financial interest/relationship or affiliation in the form of: Received consulting fees from Lilly USA; Novartis Pharmaceuticals Corp; Pfizer, Inc; Amgen, Inc; and AstraZeneca Pharmaceuticals LP.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation for Physicians

AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit
Released: March 26, 2019
Expires: March 25, 2020
15 minutes to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who treat or manage advanced or metastatic breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Describe the mechanism of action of cyclin-dependent kinase 4/6 inhibitors, including differences among available and emerging agents
  • Compare and contrast the dosing and efficacy of cyclin-dependent kinase 4/6 inhibitors for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer
  • Select the appropriate cyclin-dependent kinase 4/6 inhibitor for patients according to their efficacy, safety, and patient characteristics
  • Identify common toxicities of cyclin-dependent kinase 4/6 inhibitors for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer, including gastrointestinal toxicity and neutropenia

Activity Description

Recently, there have been significant advances in the development of agents that target critical pathways involved in resistance to endocrine therapy in HR-positive/HER2-negative breast cancer, such as cyclin-dependent kinase (CDK) 4/6 inhibitors,  palbociclib, abemaciclib, and ribociclib.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on CDK4/6 inhibitors for the treatment of advanced HR-positive/HER2-negative breast cancer.

Statement of Educational Need

The goal of this activity is to provide expert perspective on frequently asked questions pertaining to the use of CDK4 and CDK6 inhibitors for the treatment of HR-positive/HER2-negative advanced or metastatic breast cancer so clinicians gain an enhanced understanding of this disease to make the best possible treatment choices with their patients.

Faculty

Adam M. Brufsky, MD, PhD, FACP
Professor of Medicine / Associate Chief, Hematology-Oncology / Associate Director, Translational Research
University of Pittsburgh School of Medicine
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Adam M. Brufsky, MD, PhD, FACP
  • Adam M. Brufsky, MD, PhD, FACP, reported a financial interest/relationship or affiliation in the form of: Received consulting fees from Lilly USA; Novartis Pharmaceuticals Corp; Pfizer, Inc; Amgen, Inc; and AstraZeneca Pharmaceuticals LP.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation for Physicians

AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Pages